Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Brøsen

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Ugeskrift for Laeger|March 26, 1984
[Individual variations in the oxidative metabolism of drugs. Significance of monogenic polymorphism]K Brøsen
Clinical Pharmacokinetics|January 1, 1995
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2K Brøsen
Therapeutic Drug Monitoring|August 1, 1996
Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatryK Brøsen
Ugeskrift for Laeger|November 15, 1993
[CYP2D6 genotype determination]K Brøsen
British Journal of Clinical Pharmacology|October 1, 1986
Sparteine oxidation polymorphism in Greenlanders living in DenmarkK Brøsen
International Clinical Psychopharmacology|November 17, 1998
Differences in interactions of SSRIsK Brøsen
Ugeskrift for Laeger|July 14, 1999
[Clinical pharmacology--what for?]K Brøsen
Danish Medical Bulletin|October 1, 1988
The relationship between imipramine metabolism and the sparteine oxidation polymorphismK Brøsen
Ugeskrift for Laeger|February 4, 1991
[The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs]K Brøsen
The Clinical Investigator|December 1, 1993
The pharmacogenetics of the selective serotonin reuptake inhibitorsK Brøsen
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Ugeskrift for Laeger|March 26, 1984
[Individual variations in the oxidative metabolism of drugs. Significance of monogenic polymorphism]K Brøsen
Clinical Pharmacokinetics|January 1, 1995
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2K Brøsen
Therapeutic Drug Monitoring|August 1, 1996
Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatryK Brøsen
Ugeskrift for Laeger|November 15, 1993
[CYP2D6 genotype determination]K Brøsen
British Journal of Clinical Pharmacology|October 1, 1986
Sparteine oxidation polymorphism in Greenlanders living in DenmarkK Brøsen
International Clinical Psychopharmacology|November 17, 1998
Differences in interactions of SSRIsK Brøsen
Ugeskrift for Laeger|July 14, 1999
[Clinical pharmacology--what for?]K Brøsen
Danish Medical Bulletin|October 1, 1988
The relationship between imipramine metabolism and the sparteine oxidation polymorphismK Brøsen
Ugeskrift for Laeger|February 4, 1991
[The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs]K Brøsen
The Clinical Investigator|December 1, 1993
The pharmacogenetics of the selective serotonin reuptake inhibitorsK Brøsen
Pageof 15